Opinion|Videos|October 28, 2024
Luspatercept Role in the RS-Negative Population and Expert Perspectives on the Role of EPO Levels
Panelists discuss how luspatercept’s role in ring sideroblast–negative MDS populations is evolving based on recent clinical trial data, including the COMMANDS trial and PACE-MDS study, with particular attention to the impact ofEPO levels on treatment decisions and outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the role of luspatercept in the RS-negative population? When do you consider it as first-line treatment in this particular patient population?
Resource link: COMMANDS trial (Della Porta MG, et al. Lancet Haematol, 2024).
Resource link: Platzbecker U, et al. Phase II PACE-MDS study. J Clin Oncol, 2022.
Resource link: Platzbecker U, et al. Comparative biomarkers by RS status COMMANDS trial. EHA 2024, abstract P763.
- How do EPO levels factor into your treatment approach for this patient
- Please comment on outcomes in the COMMANDS trial (Della Porta MG, et al. Lancet Haematol, 2024) based on EPO levels (<200).
Advertisement
Related to this article
Breast cancer experts address frequently asked questions on adjuvant and metastatic CDK4/6 inhibitor selection in HR-positive breast cancer.
The European Commission approved pembrolizumab plus enfortumab vedotin for muscle-invasive bladder cancer, irrespective of cisplatin eligibility.
Thoracic oncologists weigh how TROP2-directed antibody-drug conjugates fit into sequencing and combination strategies for EGFR-mutated NSCLC.
Patients with pancreatic cancer experience measurable changes in body composition years before diagnosis that differ from those seen in similar individuals without cancer.
Lisaftoclax plus acalabrutinib earned breakthrough therapy status in China for untreated CLL/SLL.
Andrea Cercek, MD, discusses the FDA approval of dostarlimab and its significance for dMMR locally advanced rectal cancer management.
Fadi Haddad, MD, discusses TKI adherence barriers, adverse effect management, and the role of alternative TKI formulations in CML.
Updated ARC-20 data showed casdatifan activity as monotherapy and in combinations across treatment lines in advanced clear cell RCC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval of Dostarlimab Brings Potential Organ-Sparing Approach in dMMR Locally Advanced Rectal Cancer
2
Treatment Tailoring and Weighing Alternative Formulations Support Optimal TKI Deployment in CML
3
Casdatifan Demonstrates Activity in Advanced Clear Cell RCC
4
QTX3034 Plus Cetuximab Receives FDA Fast Track Designation in KRAS G12D–Mutated CRC
5